Laurus Labs Q3 net slides 43% as ARV sales drag

Drugmaker Laurus Labs reported a more than 43% decline in consolidated net profit to ₹154.97 crore for the quarter ended December 31, 2021.

The lower net profit, compared with the ₹272.85 crore seen a year earlier, came on the back of total income of ₹1,034.09 crore (₹1,295.35 crore). The company attributed the 20% decline in income to the transient inventory correction of the anti-retroviral (ARV) business.

Core results continued to remain resilient with strong growth in synthesis and other APIs, Laurus said in a release. CEO Satyanarayana Chava said lower sales of ARV APIs and formulations due to stocking at channel partners had affected Q3 results.

Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | May 25, 2022 8:33:55 pm |